Previous work utilizing various dominant-negative forms of TGFBRII in conjunction with CARs revealed resistance to TGFβ-mediated suppression in pre-clinical models of prostate cancer and glioblastoma (47, 48). This evidence concerns the gene TGFB1 and Familial prostate cancer.